Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.59 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MASP2 | O00187 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2674337 | 1.00 | DDAH1 (0.63) | DDAH1POLBPKMGAANPC1 | |
| Hydrochloric Acid SCHEMBL1143206 | 0.98 | PKM (0.64) | DDAH1POLBPKMGAANPC1 | |
| SCHEMBL73225 | 0.98 | DDAH1 (0.66) | DDAH1POLBPKMGAANPC1 | |
| SCHEMBL29450860 | 0.98 | DDAH1 (0.66) | DDAH1POLBPKMGAANPC1 | |
| Water SCHEMBL8757434 | 0.96 | DDAH1 (0.63) | DDAH1POLBPKMGAANPC1 | |
| Dipyridyl SCHEMBL28860984 | 0.85 | NPC1 (0.59) | DDAH1POLBPKMGAANPC1 | |
| Hydrochloric Acid SCHEMBL2454024 | 0.85 | POLB (0.70) | DDAH1POLBPKMNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL28373229 | 0.85 | POLB (0.70) | DDAH1POLBPKMNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7413158 | 0.83 | POLB (0.68) | DDAH1POLBPKMNPC1RAB9A | |
| SCHEMBL524002 | 0.82 | POLB (0.72) | DDAH1POLBGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210140052-A1 | ELECTROLESS COPPER PLATING AND COUNTERACTING PASSIVATION | ROHM AND HAAS ELECTRONIC MATERIALS LLC | 2021-05-13 | — | — | US | claimed |
| EP-3819397-A1 | ELECTROLESS COPPER PLATING AND COUNTERACTING PASSIVATION | Rohm and Haas Electronic Materials LLC (US) | 2021-05-12 | — | — | EP | claimed |
| CN-112779524-A | Electroless copper plating and offset passivation | 罗门哈斯电子材料有限责任公司 | 2021-05-11 | — | — | CN | claimed |
| CN-101875638-A | Method for synthesizing 2-aminomethyl benzimidazole by microwave irradiation | NORTHWESTAGRICULTURE AND FORESTRY UNIVERSITY | 2010-11-03 | — | — | CN | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-20260108946-A1 | LOW-TEMPERATURE CASE HARDENING OF ADDITIVE MANUFACTURED ARTICLES AND MATERIALS AND TARGETED APPLICATION OF SURFACE MODIFICATION | SWAGELOK CO (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260002244-A1 | ACTIVATION OF SELF-PASSIVATING METALS USING REAGENT COATINGS FOR LOW TEMPERATURE NITROCARBURIZATION IN THE PRESENCE OF OXYGEN-CONTAINING GAS | SWAGELOK CO (US) | 2026-01-01 | — | — | US | disclosed |
| US-12435406-B2 | Activation of self-passivating metals using reagent coatings for low temperature nitrocarburization in the presence of oxygen-containing gas | SWAGELOK COMPANY (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250297351-A1 | LASER-ASSISTED REAGENT ACTIVATION AND PROPERTY MODIFICATION OF SELF-PASSIVATING METALS | SWAGELOK COMPANY | 2025-09-25 | — | — | US | disclosed |
| US-12378463-B2 | Water-based resin with elasticity for applications in cementing and subterranean structures | SAUDI ARABIAN OIL COMPANY (SA) | 2025-08-05 | — | — | US | disclosed |
| CN-116479366-B | Chemical activation of self-passivating metals | 斯瓦戈洛克公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-114929924-B | Chemical activation of self-passivating metals | 斯瓦戈洛克公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-0761673-A1 | Cephalosporin derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-12 | — | — | EP | disclosed |
| US-5578601-A | Nonpeptide bradykinin antagonists | STERLING WINTHROP INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0709373-A1 | NOVEL PYRROLIDINE DERIVATIVE | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5510380-A | TREATING INFLAMMATORY CONDITIONS | STERLING WINTHROP, INC. (US) | 1996-04-23 | — | — | US | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| EP-0528661-A2 | HIV protease inhibitors with N-terminal polyether substituents | MERCK & CO. INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-3941788-A | Benzimidazole derivatives | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | GAA 53/4885BCHE 222/4885CHRM1 1323/4885 |
| US-20260002244-A1 | ACTIVATION OF SELF-PASSIVATING METALS USING REAGENT COATINGS FOR LOW TEMPERATURE NITROCARBURIZATION IN THE PRESENCE OF OXYGEN-CONTAINING GAS | NOS2, GSDMD, NOS1 | GAA 2271/4885BCHE 2065/4885CHRM1 219/4885 |
| US-20260108946-A1 | LOW-TEMPERATURE CASE HARDENING OF ADDITIVE MANUFACTURED ARTICLES AND MATERIALS AND TARGETED APPLICATION OF SURFACE MODIFICATION | NOS2, NIT2, NSUN2 | GAA 667/4885BCHE 1277/4885CHRM1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.